CN114206926A - 抗PDL1和TGFβ的双功能融合蛋白及其用途 - Google Patents
抗PDL1和TGFβ的双功能融合蛋白及其用途 Download PDFInfo
- Publication number
- CN114206926A CN114206926A CN202080000954.6A CN202080000954A CN114206926A CN 114206926 A CN114206926 A CN 114206926A CN 202080000954 A CN202080000954 A CN 202080000954A CN 114206926 A CN114206926 A CN 114206926A
- Authority
- CN
- China
- Prior art keywords
- antibody
- antigen
- binding fragment
- seq
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Abstract
本发明涉及抗PDL1抗体及其抗原结合片段,还涉及抗PDL1和TGFβ的双功能融合蛋白及其制备方法和用途。本发明提供的抗体或抗原结合片段或双功能融合蛋白具有以下功能中的一种或多种优势:增强的TGFβ1结合活性、增强的PDL1亲和力、增强的阻断PDL1和PD1结合的能力、增强的阻断TGFβ1功能活性、增强的促进T细胞分泌IFN‑γ的能力、更好的免疫调节效果、更好的肿瘤抑瘤效果。
Description
PCT国内申请,说明书已公开。
Claims (10)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910497064 | 2019-06-10 | ||
CN201910497064X | 2019-06-10 | ||
CN201910497723 | 2019-06-10 | ||
CN201910497723X | 2019-06-10 | ||
PCT/CN2020/094855 WO2020248926A1 (zh) | 2019-06-10 | 2020-06-08 | 抗PDL1和TGFβ的双功能融合蛋白及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114206926A true CN114206926A (zh) | 2022-03-18 |
CN114206926B CN114206926B (zh) | 2022-06-17 |
Family
ID=73780650
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202080000954.6A Active CN114206926B (zh) | 2019-06-10 | 2020-06-08 | 抗PDL1和TGFβ的双功能融合蛋白及其用途 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20220213195A1 (zh) |
EP (1) | EP3929215A4 (zh) |
JP (1) | JP7297090B2 (zh) |
KR (1) | KR20220007118A (zh) |
CN (1) | CN114206926B (zh) |
AU (1) | AU2020290119A1 (zh) |
BR (1) | BR112021024820A2 (zh) |
CA (1) | CA3135988A1 (zh) |
WO (1) | WO2020248926A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3990116A1 (en) * | 2019-06-28 | 2022-05-04 | Gensun Biopharma Inc. | ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFß1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD |
CN115175942A (zh) * | 2020-02-25 | 2022-10-11 | 上海药明生物技术有限公司 | 一种双功能融合蛋白及其用途 |
WO2023009891A2 (en) * | 2021-07-30 | 2023-02-02 | Janssen Biotech, Inc. | Materials and methods of making or using il-23r binding proteins |
CN116063526A (zh) * | 2022-12-31 | 2023-05-05 | 合肥天港免疫药物有限公司 | 抗pdl1的抗体及其用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019101196A1 (zh) * | 2017-11-27 | 2019-05-31 | 山东博安生物技术有限公司 | 抗pd-l1的抗体及其用途 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104356236B (zh) * | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
KR101573109B1 (ko) * | 2009-11-24 | 2015-12-01 | 메디뮨 리미티드 | B7―h1에 대한 표적화된 결합 물질 |
LT2785375T (lt) * | 2011-11-28 | 2020-11-10 | Merck Patent Gmbh | Anti-pd-l1 antikūnai ir jų panaudojimas |
CN115093480A (zh) * | 2012-05-31 | 2022-09-23 | 索伦托药业有限公司 | 与pd-l1结合的抗原结合蛋白 |
CN103571872B (zh) | 2012-08-09 | 2016-11-23 | 山东国际生物科技园发展有限公司 | 一种能够表达人抗体的转基因动物的制备方法 |
RU2021114500A (ru) * | 2014-02-10 | 2021-06-07 | Мерк Патент Гмбх | НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ |
CU20170052A7 (es) * | 2014-10-14 | 2017-11-07 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo que se unen a pd-l1 |
WO2017020291A1 (en) * | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
AR105654A1 (es) * | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
CN106939047B (zh) * | 2016-01-04 | 2021-08-31 | 江苏怀瑜药业有限公司 | 一种pd-l1抗体及其制备方法 |
RU2019106663A (ru) * | 2016-08-12 | 2020-09-14 | Мерк Патент Гмбх | Комбинированная терапия рака |
BR112019013924A2 (pt) * | 2017-01-07 | 2020-02-11 | Merck Patent Gmbh | Regimes de dosagem e formas de dosagem para inibição de tgf-beta direcionada |
MX2019013023A (es) * | 2017-05-12 | 2019-12-18 | Jiangsu Hengrui Medicine Co | Proteina de fusion con receptor tgf-?, y uso farmaceutico de la misma. |
EP3630148A4 (en) * | 2017-05-26 | 2021-06-16 | The Johns Hopkins University | MULTIFUNCTIONAL ANTIBODY LIGAND TRAPS FOR THE MODULATION OF IMMUNTOLERANCE |
-
2020
- 2020-06-08 CN CN202080000954.6A patent/CN114206926B/zh active Active
- 2020-06-08 EP EP20822451.9A patent/EP3929215A4/en active Pending
- 2020-06-08 CA CA3135988A patent/CA3135988A1/en active Pending
- 2020-06-08 US US17/601,891 patent/US20220213195A1/en active Pending
- 2020-06-08 JP JP2021560523A patent/JP7297090B2/ja active Active
- 2020-06-08 WO PCT/CN2020/094855 patent/WO2020248926A1/zh unknown
- 2020-06-08 KR KR1020217040151A patent/KR20220007118A/ko unknown
- 2020-06-08 BR BR112021024820A patent/BR112021024820A2/pt unknown
- 2020-06-08 AU AU2020290119A patent/AU2020290119A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019101196A1 (zh) * | 2017-11-27 | 2019-05-31 | 山东博安生物技术有限公司 | 抗pd-l1的抗体及其用途 |
Also Published As
Publication number | Publication date |
---|---|
CA3135988A1 (en) | 2020-12-17 |
JP2022528007A (ja) | 2022-06-07 |
CN114206926B (zh) | 2022-06-17 |
JP7297090B2 (ja) | 2023-06-23 |
AU2020290119A1 (en) | 2021-10-07 |
EP3929215A4 (en) | 2022-06-22 |
BR112021024820A2 (pt) | 2022-01-25 |
EP3929215A1 (en) | 2021-12-29 |
KR20220007118A (ko) | 2022-01-18 |
WO2020248926A1 (zh) | 2020-12-17 |
US20220213195A1 (en) | 2022-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114206926B (zh) | 抗PDL1和TGFβ的双功能融合蛋白及其用途 | |
CN108124445B (zh) | Ctla4抗体、其药物组合物及其用途 | |
CN110366560B (zh) | 抗b7-h4抗体、其抗原结合片段及其医药用途 | |
JP2022535858A (ja) | 抗b7-h4抗体-薬物コンジュゲート及びその医薬的使用 | |
CN110156895B (zh) | 一种抗pd-l1抗体或其功能性片段及其用途 | |
CN111065652A (zh) | 抗4-1bb抗体、其抗原结合片段及其医药用途 | |
JP7009642B2 (ja) | 抗-vista抗体及びその用途 | |
CA3068932A1 (en) | Bispecific anti pd1-anti tim3 antibodies | |
CN113508139A (zh) | 结合人lag-3的抗体、其制备方法和用途 | |
CN114790242A (zh) | 一种结合人pd-l1的抗体 | |
CN109021107B (zh) | 一种特异性结合人pd-l1的单克隆抗体及包含其的药物和试剂盒 | |
Cho et al. | Generation, characterization and preclinical studies of a human anti-L1CAM monoclonal antibody that cross-reacts with rodent L1CAM | |
CN111344305B (zh) | 抗pd-l1的抗体及其用途 | |
CN114174335A (zh) | 一种人源化vegfr2抗体及其应用 | |
Chen et al. | A dual-specific IGF-I/II human engineered antibody domain inhibits IGF signaling in breast cancer cells | |
CN113754770B (zh) | 一种特异性结合人ctla4的抗体及包含其的药物和试剂盒 | |
KR102291725B1 (ko) | 항-cntn4 항체 및 그의 용도 | |
WO2022042715A1 (zh) | 靶向PD-L1和TGFβ的双功能融合蛋白及其制备方法与应用 | |
EP3919514A1 (en) | Recombinant anti-human pd-1 antibody and application thereof | |
KR20220007120A (ko) | 항-cd25 항체 및 이의 적용 | |
CN113234160B (zh) | 一种抗pd-1抗体及其应用 | |
AU2018239725B2 (en) | Anti-DR5 antibody and use thereof | |
CN115536746A (zh) | 抗crtam抗体及其应用 | |
KR20220118962A (ko) | Pd-l1에 대한 단일 도메인 항체 및 이의 용도 | |
CN116478288A (zh) | 红细胞弱结合型人源化cd47抗体及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |